BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
August 21 2024 - 10:02AM
Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the
“Company”) today announced that it has signed a letter of intent to
supply its DEA-approved marijuana extracts and plant-based
psychedelics to Benuvia Operations, a FDA registered, DEA licensed
and cGMP certified leader in pharmaceutical cannabinoids, as well
as psychedelic molecules currently under investigation for clinical
use.
This completely homegrown agreement signals
Bright Green’s ability and commitment to supply US pharmaceutical
partners with high quality organic materials. As part of the supply
agreement proposed in the LOI, Benuvia intends to leverage Bright
Green’s unique position to produce Schedule I & II raw
materials in full compliance with Good Agricultural and Collection
Practices (GACP), Good Manufacturing Practices (GMP), and the DEA,
all within the USA, to produce domestically manufactured cGMP
pharmaceutical-grade Active Pharmaceutical Ingredients (“APIs”) for
US and global markets.
Bright Green sees this as yet another step
towards becoming the leading domestic supplier of DEA controlled,
plant-based raw materials to produce cannabinoid, psychedelic and
opioid based drugs in the USA. With a new round of fundraising and
supply agreements in the works, Bright Green is positioned for a
strong performance in 2025.
The Drug Enforcement Administration (DEA) just
completed its annual operational procedures for all its Schedule I
& II drug cultivation and manufacturing in July. Bright Green
meets this high national standard and is now one step closer to
beginning operations and supplying the pharmaceutical world with
the materials it needs to innovate.
ABOUT BRIGHT GREEN CORPORATION
Bright Green is one of the few companies
authorized by the US government and the New Mexico Board of
Pharmacy to grow, manufacture, and sell, legally under federal and
state law, Schedule I and II plant-based drugs for research,
pharmaceutical applications, and affiliated export. Bright Green’s
approval from the U.S. Drug Enforcement Administration gives them
the opportunity to advance their vision of improving quality of
life through the opportunities presented by cannabis and other
plant based derived therapies and more. To learn more, visit
www.brightgreen.us
ABOUT BENUVIA
Benuvia Operations, LLC is a pioneering leader
in the research, development, and commercialization of innovative
pharmaceutical products across a wide range of therapeutic areas.
Benuvia is committed to improving patient outcomes through rigorous
scientific study and quality manufacturing practices. With FDA
registration, DEA licensing, and cGMP certification, Benuvia
operates at the forefront of the pharmaceutical industry. Benuvia's
flagship product, SYNDROS, is an FDA-approved medication used for
the treatment of anorexia associated with weight loss in patients
with AIDS and for managing chemotherapy-induced nausea and
vomiting. To learn more, visit www.benuvia.com.
Media Inquiries & Investor Relations
Contactir@brightgreen.us
Bright Green (NASDAQ:BGXX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bright Green (NASDAQ:BGXX)
Historical Stock Chart
From Aug 2023 to Aug 2024